Tag: FDA-approved lymphoma drugs 2024

Home / FDA-approved lymphoma drugs 2024

Categories

Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refra...
fda-approved-lymphoma-drugs-2024

Scan the code